Screener
Altimmune ALT Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 16,192 | 15,827 |
| General and administrative | 8,052 | 5,993 |
| Total operating expenses | 24,244 | 21,820 |
| Loss from operations | (24,244) | (21,815) |
| Other income (expense): | ||
| Interest expense | (1,068) | (1) |
| Interest income | 2,901 | 1,545 |
Item 1. Financial Statements
FAQ
- What is Altimmune's other operating expenses?
- Altimmune (ALT) reported other operating expenses of $24.24M in Q1 2026.
- How has Altimmune's other operating expenses changed year-over-year?
- Altimmune's other operating expenses increased by 11.1% year-over-year, from $21.82M to $24.24M.
- What is the long-term trend for Altimmune's other operating expenses?
- Over 4 years (2021 to 2025), Altimmune's other operating expenses has grown at a -1.7% compound annual growth rate (CAGR), from $101.32M to $94.53M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Altimmune's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude